Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project

Health and Quality of Life Outcomes

Arthur J Davidson²  Allyn K Nakashima¹  Michael L Campsmith¹ 

[1] Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA;Denver Department of Public Health, Denver, Colorado, USA

关键词: antiretroviral therapy;    quality of life;    HIV/AIDS;   

Others  :  1217157
DOI  :  10.1186/1477-7525-1-12

 received in 2003-03-27, accepted in 2003-04-24,  发布年份 2003

【 摘 要 】

Background

To examine demographic and behavioral associations with self-reported health-related quality of life (HRQOL) among persons with HIV infection or AIDS.

Methods

Analysis of interviews with persons ≥ 18 years of age reported through routine disease surveillance with HIV infection or AIDS to nine state and local health departments from January 1995 through December 1996. Scales were constructed from validated measures of HRQOL, and mean scores were calculated (lower scores signified poorer HRQOL). Measures of HRQOL included Overall Health, Pain, Physical Functioning, Role Functioning, Social Functioning, Mental Health, Energy/Fatigue, and Cognitive Functioning. Differences in HRQOL were examined by various demographic and behavioral factors, including taking antiretroviral medication.

Results

HRQOL data were available for 3778 persons. Factors associated with lower HRQOL scores included older age, female sex, black or Hispanic race/ethnicity, injection drug use, lower education and income, no private health insurance, and lower CD4 count. In multivariate analysis, lower CD4 count was the factor most consistently associated with lower HRQOL. Taking antiretroviral medication was not associated with differences in HRQOL regardless of CD4 count.

Conclusions

Perception of HRQOL varied in a population with HIV infection or AIDS. On most HRQOL measures, lower CD4 count was associated with lower HRQOL. Measurement of HRQOL can assist in understanding the long-term effects of disease and treatment on persons with HIV.

【 授权许可】

   
2003 Campsmith et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
• [2]Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors. A review for clinicians. JAMA 1997, 277:145-153.
• [3]Saag MS, Schooley RT: Antiretroviral chemotharapy. Current Clinical Topics Infectious Diseases 1998, 18:154-179.
• [4]Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report. 2000, 12(2):38-39.
• [5]Centers for Disease Control and Prevention: Guidelines for the using antiretroviral agents among HIV-infected adults and adolescents recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR 2002, 51(RR-7):5-12.
• [6]Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA: Health-related quality of life with coronary heart disease prevention and treatment. J Clinical Epidemiology 2001, 54:1011-1018.
• [7]Janz NK, Janevic MR, Dodge JA, et al.: Factors influencing quality of life in older women with heart disease. Medical Care 2001, 39:588-598.
• [8]Strand V, Tugwell P, Bombardier C, et al.: Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism 1999, 42:1870-1878.
• [9]Gregg EW, Beckles GL, Williamson DF, et al.: Diabetes and physical disability among older U.S. adults. Diabetes Care 2000, 23:1272-1277.
• [10]Rapp SR, Feldman SR, Exum ML, Fleisher AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. Journal American Academy Dermatology 1999, 41:401-407.
• [11]Arora NK, Gustafson DH, Hawkins RP, et al.: Impact of surgery on the quality of life of younger women with breast carcinoma: a prospective study. Cancer 2001, 92:1288-1298.
• [12]Tsevat J, Sherman SN, McElwee JA, et al.: The will to live among HIV-infected patients. Annuals Internal Medicine 1999, 131:194-198.
• [13]Call SA, Klapow JC, Stewart KE, et al.: Health-related quality of life and virologic outcomes in an HIV clinic. Quality of Life Research 2000, 9:977-985.
• [14]Brechtl JR, Breitbart W, Galietta M, Krivo S, Rosenfeld B: The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. Journal Pain & Symptom Management 2001, 21:41-51.
• [15]Wu AW, Rubin HR, Mathews WC, et al.: Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. JAIDS 1993, 6:452-458.
• [16]Bozzette SA, Kanouse DE, Berry S, Duan N: Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. JAMA 1995, 273:295-301.
• [17]Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P: A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. AIDS 1998, 12:1495-1502.
• [18]Revicki DA, Moyle G, Stellbrink HJ: Quality of life outcomes of combination zalcitabine-zidovudine, sasquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. AIDS 1999, 13:851-858.
• [19]Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C: Quality of life in persons with human immunodeficiency virus infection: measurement by the medical outcomes study instrument. Annals Internal Medicine 1992, 116:129-137.
• [20]Hays RD, Cunningham WE, Sherbourne CD, et al.: Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. American Journal Medicine 2000, 108:714-722.
• [21]Lubeck DP, Fries JF: Health status among persons infected with human immunodeficiency virus. A community-based study. Medical Care 1993, 31:269-276.
• [22]Buehler JW, Diaz T, Hersh BS, et al.: The supplement to HIV/AIDS surveillance project: an approach for monitoring HIV risk behaviors. Public Health Rep 1996, 111(Suppl 1):134-137.
• [23]Wu AW, Rubin HR, Mathews WC, et al.: A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care 1991, 29:786-798.
• [24]Stewart AL, Hays RD, Ware JE: The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988, 26:724-735.
• [25]Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16:297-334.
• [26]Weinfurt KP, Wilke RJ, Glick HA, Freimuth WW, Schulman KA: Relationship between CD4 count, viral burden and quality of life over time in HIV-1-infected patients. Med Care 2000, 38:404-410.
• [27]Low-Beer S, Chan K, Wood E, et al.: Health related quality of life among persons with HIV after the use of protease inhibitors. Quality of Life Research 2000, 9:941-949.
• [28]Bing EG, Hays RD, Jacobson LP, et al.: Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study. Quality of Life Research 2000, 9:55-63.
• [29]Holzmer WL, Corless IB, Nokes KM, et al.: Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care & STDs 1999, 13:185-197.
• [30]Bucciardini R, Wu AW, Floridia M, et al.: Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudine-didanosine for antriretroviral-naive advanced HIV-infected patients. AIDS 2000, 14:2567-2574.
• [31]Swindells S, Mohr J, Justis JC, et al.: Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness. Int J STD AIDS 1999, 10:383-391.
• [32]Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL: Patterns, correlates, and barriers to medication adherence among persons prescribed new treatment for HIV disease. Health Psychology 2000, 19:124-133.